BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 16316989)

  • 1. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
    Klumpp K; Lévêque V; Le Pogam S; Ma H; Jiang WR; Kang H; Granycome C; Singer M; Laxton C; Hang JQ; Sarma K; Smith DB; Heindl D; Hobbs CJ; Merrett JH; Symons J; Cammack N; Martin JA; Devos R; Nájera I
    J Biol Chem; 2006 Feb; 281(7):3793-9. PubMed ID: 16316989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
    Le Pogam S; Jiang WR; Leveque V; Rajyaguru S; Ma H; Kang H; Jiang S; Singer M; Ali S; Klumpp K; Smith D; Symons J; Cammack N; Nájera I
    Virology; 2006 Aug; 351(2):349-59. PubMed ID: 16713611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
    Murakami E; Bao H; Ramesh M; McBrayer TR; Whitaker T; Micolochick Steuer HM; Schinazi RF; Stuyver LJ; Obikhod A; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):503-9. PubMed ID: 17101674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.
    Klumpp K; Kalayanov G; Ma H; Le Pogam S; Leveque V; Jiang WR; Inocencio N; De Witte A; Rajyaguru S; Tai E; Chanda S; Irwin MR; Sund C; Winqist A; Maltseva T; Eriksson S; Usova E; Smith M; Alker A; Najera I; Cammack N; Martin JA; Johansson NG; Smith DB
    J Biol Chem; 2008 Jan; 283(4):2167-75. PubMed ID: 18003608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
    Smith DB; Martin JA; Klumpp K; Baker SJ; Blomgren PA; Devos R; Granycome C; Hang J; Hobbs CJ; Jiang WR; Laxton C; Le Pogam S; Leveque V; Ma H; Maile G; Merrett JH; Pichota A; Sarma K; Smith M; Swallow S; Symons J; Vesey D; Najera I; Cammack N
    Bioorg Med Chem Lett; 2007 May; 17(9):2570-6. PubMed ID: 17317178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor.
    Chen Y; Bopda-Waffo A; Basu A; Krishnan R; Silberstein E; Taylor DR; Talele TT; Arora P; Kaushik-Basu N
    Antivir Chem Chemother; 2009 Sep; 20(1):19-36. PubMed ID: 19794229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.
    Carroll SS; Tomassini JE; Bosserman M; Getty K; Stahlhut MW; Eldrup AB; Bhat B; Hall D; Simcoe AL; LaFemina R; Rutkowski CA; Wolanski B; Yang Z; Migliaccio G; De Francesco R; Kuo LC; MacCoss M; Olsen DB
    J Biol Chem; 2003 Apr; 278(14):11979-84. PubMed ID: 12554735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication.
    Nilsson M; Kalayanov G; Winqvist A; Pinho P; Sund C; Zhou XX; Wähling H; Belfrage AK; Pelcman M; Agback T; Benckestock K; Wikström K; Boothee M; Lindqvist A; Rydegård C; Jonckers TH; Vandyck K; Raboisson P; Lin TI; Lachau-Durand S; de Kock H; Smith DB; Martin JA; Klumpp K; Simmen K; Vrang L; Terelius Y; Samuelsson B; Rosenquist S; Johansson NG
    Bioorg Med Chem Lett; 2012 May; 22(9):3265-8. PubMed ID: 22472694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
    Smith DB; Kalayanov G; Sund C; Winqvist A; Pinho P; Maltseva T; Morisson V; Leveque V; Rajyaguru S; Le Pogam S; Najera I; Benkestock K; Zhou XX; Maag H; Cammack N; Martin JA; Swallow S; Johansson NG; Klumpp K; Smith M
    J Med Chem; 2009 Jan; 52(1):219-23. PubMed ID: 19055482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
    McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
    Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine.
    Smith DB; Kalayanov G; Sund C; Winqvist A; Maltseva T; Leveque VJ; Rajyaguru S; Le Pogam S; Najera I; Benkestock K; Zhou XX; Kaiser AC; Maag H; Cammack N; Martin JA; Swallow S; Johansson NG; Klumpp K; Smith M
    J Med Chem; 2009 May; 52(9):2971-8. PubMed ID: 19341305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase.
    Shim J; Larson G; Lai V; Naim S; Wu JZ
    Antiviral Res; 2003 May; 58(3):243-51. PubMed ID: 12767472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.
    Ma H; Leveque V; De Witte A; Li W; Hendricks T; Clausen SM; Cammack N; Klumpp K
    Virology; 2005 Feb; 332(1):8-15. PubMed ID: 15661135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
    Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.